Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 322.53
ACHN's Cash to Debt is ranked higher than
76% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. ACHN: 322.53 )
ACHN' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 322.53

F-Score: 2
Z-Score: 54.06
M-Score: -4.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -50.71
ACHN's ROE (%) is ranked higher than
69% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. ACHN: -50.71 )
ACHN' s 10-Year ROE (%) Range
Min: -199.15   Max: -46.56
Current: -50.71

-199.15
-46.56
ROA (%) -47.07
ACHN's ROA (%) is ranked higher than
66% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. ACHN: -47.07 )
ACHN' s 10-Year ROA (%) Range
Min: -181.02   Max: -43.23
Current: -47.07

-181.02
-43.23
ROC (Joel Greenblatt) (%) -4805.90
ACHN's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. ACHN: -4805.90 )
ACHN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6066.62   Max: -465.75
Current: -4805.9

-6066.62
-465.75
EBITDA Growth (3Y)(%) 1.00
ACHN's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -7.20 vs. ACHN: 1.00 )
ACHN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 4.1
Current: 1

0
4.1
EPS Growth (3Y)(%) 0.50
ACHN's EPS Growth (3Y)(%) is ranked higher than
81% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. ACHN: 0.50 )
ACHN' s 10-Year EPS Growth (3Y)(%) Range
Min: -65.5   Max: 3.4
Current: 0.5

-65.5
3.4
» ACHN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ACHN Guru Trades in Q1 2014

Steven Cohen 43,533 sh (New)
Paul Tudor Jones Sold Out
Jean-Marie Eveillard Sold Out
Chuck Royce 500,000 sh (-15.25%)
» More
Q2 2014

ACHN Guru Trades in Q2 2014

Paul Tudor Jones 26,592 sh (New)
Steven Cohen 547,200 sh (unchged)
Chuck Royce 2,262 sh (-99.55%)
» More
Q3 2014

ACHN Guru Trades in Q3 2014

Jim Simons 897,300 sh (New)
Steven Cohen 1,048,100 sh (+91.54%)
Paul Tudor Jones 45,217 sh (+70.04%)
Chuck Royce 2,262 sh (unchged)
» More
Q4 2014

ACHN Guru Trades in Q4 2014

John Burbank 36,104 sh (New)
John Burbank 207,000 sh (unchged)
Jim Simons Sold Out
Chuck Royce Sold Out
Steven Cohen 621,900 sh (-40.66%)
Paul Tudor Jones 13,942 sh (-69.17%)
» More
» Details

Insider Trades

Latest Guru Trades with ACHN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.20
ACHN's P/B is ranked higher than
61% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. ACHN: 7.20 )
ACHN' s 10-Year P/B Range
Min: 0.79   Max: 17.77
Current: 7.2

0.79
17.77
EV-to-EBIT -16.52
ACHN's EV-to-EBIT is ranked higher than
54% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACHN: -16.52 )
ACHN' s 10-Year EV-to-EBIT Range
Min: -25.5   Max: 0.6
Current: -16.52

-25.5
0.6
Current Ratio 11.86
ACHN's Current Ratio is ranked higher than
90% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ACHN: 11.86 )
ACHN' s 10-Year Current Ratio Range
Min: 1.06   Max: 13.27
Current: 11.86

1.06
13.27
Quick Ratio 11.86
ACHN's Quick Ratio is ranked higher than
90% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. ACHN: 11.86 )
ACHN' s 10-Year Quick Ratio Range
Min: 1.06   Max: 13.27
Current: 11.86

1.06
13.27

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.20
ACHN's Price/Net Cash is ranked higher than
82% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 93.33 vs. ACHN: 7.20 )
ACHN' s 10-Year Price/Net Cash Range
Min: 0.82   Max: 12.7
Current: 7.2

0.82
12.7
Price/Net Current Asset Value 7.20
ACHN's Price/Net Current Asset Value is ranked higher than
80% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 39.86 vs. ACHN: 7.20 )
ACHN' s 10-Year Price/Net Current Asset Value Range
Min: 0.78   Max: 12.29
Current: 7.2

0.78
12.29
Price/Tangible Book 7.40
ACHN's Price/Tangible Book is ranked higher than
67% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. ACHN: 7.40 )
ACHN' s 10-Year Price/Tangible Book Range
Min: 0.72   Max: 77.75
Current: 7.4

0.72
77.75
Earnings Yield (Greenblatt) -6.50
ACHN's Earnings Yield (Greenblatt) is ranked higher than
68% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. ACHN: -6.50 )
ACHN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -6.6   Max: 2697.4
Current: -6.5

-6.6
2697.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ADA.Germany,
Achillion Pharmaceuticals Inc was incorporated on August 17, 1998 in Delaware. The Company is a biopharmaceutical company which focuses on the discoveries, develops and commercializes treatments for infectious diseases. Within the anti-infective market, it is currently focusing its efforts on developing commercially competitive, short-duration combination therapies for the treatment of chronic hepatitis C infection that are administered once-daily, orally, and without ribavirin. The Company competes with Abbvie, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Enanta, Gilead, GlaxoSmithKline, Idenix, Johnson & Johnson, Presidio, Medivir, Merck, Novartis, Pfizer, Roche, Valeant and Vertex. The Company's drug candidates is subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, record keeping, labeling, marketing and distribution of drugs.
» More Articles for ACHN

Headlines

Articles On GuruFocus.com
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
comment on ACHN Mar 15 2013 
comment on ACHN Mar 09 2013 
Achillion Will Surge If New Drug Is Successful Apr 22 2012 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 24 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 


More From Other Websites
Nasdaq stocks posting largest percentage decreases Mar 27 2015
Most active Nasdaq-traded stocks Mar 27 2015
Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog Mar 27 2015
Steadymed Ltd (STDY), Achillion Pharmaceuticals, Inc. (ACHN), & Nevro Corp (NVRO): James Flynn’s... Mar 27 2015
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 24 2015
Lightning Round: Too much competition in this Mar 20 2015
Cramer Remix: Cha-ching! Time to cash in Mar 20 2015
ACHILLION PHARMACEUTICALS INC Financials Mar 13 2015
Express Scripts Issues Report on Prescription Drug Spending - Analyst Blog Mar 11 2015
10-K for Achillion Pharmaceuticals, Inc. Mar 07 2015
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 05 2015
Achillion Pharmaceuticals (ACHN) Stock Tanking Today on Heavy Volume Mar 05 2015
Achillion Reports 2014 Fourth Quarter and Year-End Financial Results Mar 05 2015
Should You Sell Achillion Pharmaceuticals (ACHN) Before Earnings? - Tale of the Tape Mar 05 2015
Achillion reports 4Q loss Mar 05 2015
Achillion Reports 2014 Fourth Quarter and Year-End Financial Results Mar 05 2015
Coverage initiated on Achillion Pharma by Barclays Mar 04 2015
Biotech Making A Comeback - Here Is One Stock to Watch Feb 26 2015
Achillion Pharmaceuticals Announces Closing of Public Offering of Common Stock Feb 18 2015
Achillion Pharmaceuticals Announces Closing of Public Offering of Common Stock Feb 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK